natgillin/translations-raw huggingface dataset:
Generally calcium and vitamin D supplements are advised in women with a low dietary intake.
Ženskam, ki s hrano vnašajo majhne koli ine kalcija in vitamina D, na splošno svetujemo, naj jemljejo dodatke kalcija in vitamina D.
Use in renal impairment:
Uporaba pri ledvi ni okvari:
OPTRUMA should not be used in patients with severe renal impairment (see section 4.3).
Zdravila OPTRUMA ne smemo uporabljati pri bolnikih s hudo ledvi no okvaro (glejte poglavje 4. 3).
In patients with moderate and mild renal impairment, OPTRUMA should be used with caution.
Zdravilo OPTRUMA moramo uporabljati previdno pri bolnikih z zmerno in blago ledvi no okvaro.
OPTRUMA should not be used in patients with hepatic impairment (see section 4.3).
Zdravila OPTRUMA ne smemo uporabljati pri bolnikih z jetrno okvaro (glejte poglavje 4. 3).
Hypersensitivity to the active substance or to any of the excipients.
Preob utljivost za zdravilno u inkovino ali katerokoli pomožno snov.
2 Hepatic impairment including cholestasis.
2 Aktivni venski tromboemboli ni zapleti ali venski tromboemboli ni zapleti v anamnezi, vklju no s trombozo globokih ven, plju no embolijo in trombozo retinalnih ven.
Severe renal impairment.
Huda ledvi na okvara.
OPTRUMA should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Zdravila OPTRUMA ne bi smeli uporabljati pri bolnicah, ki kažejo znake ali imajo simptome raka endometrija, saj varnost zdravila pri tej skupini bolnic še ni bila zadosti raziskana.
The risk-benefit balance should be considered in patients at risk of venous thromboembolic events of any aetiology.
Pri bolnicah, pri katerih obstaja tveganje za pojav venskih tromboemboli nih zapletov kakršnekoli etiologije, je treba upoštevati razmerje med koristnostjo jemanja zdravila in tveganjem, ki ga jemanje zdravila povzro a.
OPTRUMA should be discontinued in the event of an illness or a condition leading to a prolonged period of immobilisation.
Zdravilo OPTRUMA je treba prenehati jemati pri katerikoli bolezni ali motnji, ki vodi do daljše imobilizacije bolnice.
Discontinuation should happen as soon as possible in case of the illness, or from 3 days before the immobilisation occurs.
3 dni pred za etkom obdobja imobilizacije.
In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, overall mortality, including overall cardiovascular mortality, or stroke, compared to placebo.
V študiji pri postmenopavzalnih ženskah z dokumentirano koronarno sr no boleznijo ali z ve jim tveganjem za koronarne dogodke raloksifen v primerjavi s placebom ni vplival na incidenco miokardnega infarkta, hospitaliziranega akutnega koronarnega sindroma, celotne smrtnosti, vklju no s celotno sr nožilno smrtnostjo, ali kapi.
However, there was an increase in death due to stroke in women assigned to raloxifene.
Vendar je bilo pri ženskah, ki so dobivale raloksifen, ve smrti zaradi kapi.
This finding should be considered when prescribing raloxifene for postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation.
To ugotovitev je potrebno upoštevati pri predpisovanju raloksifena postmenopavzalnim ženskam z anamnezo kapi ali drugih zna ilnih dejavnikov tveganja za kap, kot so na primer tranzitorna ishemi na ataka ali atrijska fibrilacija.
Any uterine bleeding during OPTRUMA therapy is unexpected and should be fully investigated by a specialist.
Vsakršna krvavitev iz maternice med terapijo z zdravilom OPTRUMA je nepri akovana in jo mora v celoti raziskati specialist.
In postmenopausal women who received raloxifene treatment for 4 years, benign endometrial polyps were reported in 0.9% compared to 0.3% in women who received placebo treatment.
Pri ženskah po menopavzi, ki so bile 4 leta zdravljene z raloksifenom, so poro ali o benignih polipih endometrija v 0, 9% primerov v primerjavi z 0, 3% primerov pri ženskah, ki so prejemale le placebo.
The increase correlated with total bilirubin concentrations.
Pove anje je bilo v korelaciji s koncentracijami celokupnega bilirubina.
Until safety and efficacy have been evaluated further in patients with hepatic insufficiency, the use of OPTRUMA is not recommended in this patient population.
Dokler varnost in u inkovitost zdravila pri bolnicah z jetrno insuficienco ne bosta bolje raziskani, ne priporo amo uporabe zdravila OPTRUMA pri tej vrsti bolnic.
Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed.
Med zdravljenjem je treba skrbno spremljati vrednosti serumskih koncentracij celokupnega bilirubina, gama- glutamil transferaze, alkalne fosfataze, ALT in AST, e pri bolnici ugotovimo povišane vrednosti.
Limited clinical data suggest that in patients with a history of oral oestrogen-induced hypertriglyceridemia (> 5.6 mmol/ l), raloxifene may be associated with a marked increase in serum triglycerides.
Omejeno število klini nih podatkov kaže, da je pri bolnicah, ki so že imele s peroralnimi estrogeni povzro eno hipertrigliceridemijo (> 5, 6 mmol/ l), raloksifen lahko povezan z znatno pove animi serumskimi trigliceridi.
The safety of OPTRUMA in patients with breast cancer has not been adequately studied.
Zadostnih študij o varnosti zdravila OPTRUMA pri bolnicah z rakom dojke ni.
No data are available on the concomitant use of OPTRUMA and agents used in the treatment of early or advanced breast cancer.
Tako ni podatkov o so asnem zdravljenju z zdravilom OPTRUMA in drugimi zdravili, ki se uporabljajo za zdravljenje
Therefore, OPTRUMA should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed.
Zdravilo OPTRUMA se za zdravljenje in prepre evanje osteoporoze lahko uporablja le po zaklju enem zdravljenju raka dojke, vklju no z vso spremljajo o terapijo.
As safety information regarding co-administration of raloxifene with systemic oestrogens is limited such use is not recommended
Ker so informacije v zvezi z varnostjo ob so asnem jemanju raloksifena s sistemskimi estrogeni omejene, takšne kombinacije zdravljenja ne priporo amo.
3 OPTRUMA is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with oestrogen deficiency.
OPTRUMA ni u inkovito zdravilo za zmanjševanje vazodilatacije (navalov vro ine) ali drugih simptomov menopavze, ki so povezani s pomanjkanjem estrogena.
Optruma contains lactose.
Zdravilo OPTRUMA vsebuje laktozo.
Concurrent administration of either calcium carbonate or aluminium and magnesium-hydroxide containing antacids do not affect the systemic exposure of raloxifene.
So asna uporaba antacidov, ki vsebujejo bodisi kalcijev karbonat bodisi aluminij in magnezijev hidroksid, ne vpliva na sistemsko razpoložljivost raloksifena.
However, modest decreases in the prothrombin time have been observed, and if raloxifene is given concurrently with warfarin or other coumarin derivatives, the prothrombin time should be monitored.
So asna uporaba raloksifena in varfarina ne spremeni farmakokinetike nobene od teh snovi, opaženo pa je bilo zmerno skrajšanje protrombinskega asa. e bolnico zdravimo so asno z raloksifenom in varfarinom ali drugimi kumarinskimi derivati, je torej treba spremljati protrombinski as.
Effects on prothrombin time may develop over several weeks if OPTRUMA treatment is started in patients who are already on coumarin anticoagulant therapy.
Vplivi na protrombinski as se lahko pokažejo šele ez nekaj tednov, e zdravljenje z zdravilom OPTRUMA uvedemo pri bolnicah, ki so že na kumarinski antikoagulantni terapiji.
Raloxifene does not affect the steady-state AUC of digoxin.
Raloksifen ne vpliva na AUC v stanju dinami nega ravnovesja za digoksin.
The Cmax of digoxin increased by less than 5%.
Cmax digoksina se je pove ala za manj kot 5%.
The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the prevention and treatment trials.
Vplive drugih so asno danih zdravil na plazemske koncentracije raloksifena so ugotavljali v klini nih raziskavah preventive in zdravljenja.
Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines.
Zdravila, ki so jih pogosto dajali so asno, so bila: paracetamol, nesteroidna protivnetna zdravila (kakor so npr. acetilsalicilna kislina, ibuprofen in naproksen), peroralni antibiotiki, antagonisti H1 receptorjev, antagonisti H2 receptorjev in benzodiazepini.
No clinically relevant effects of the co-administration of the agents on raloxifene plasma concentrations were identified.
V teh raziskavah niso ugotovili nobenih klini no pomembnih u inkov so asne uporabe naštetih zdravil na plazemske koncentracije raloksifena.
Concomitant use of vaginal oestrogen preparations was allowed in the clinical trial programme, if necessary to treat atrophic vaginal symptoms.
V programu klini nih raziskav je bila so asna uporaba vaginalnih pripravkov estrogena dovoljena, e je bilo to potrebno zaradi zdravljenja simptomov vaginalne atrofije.
Compared to placebo there was no increased use in OPTRUMA treated patients.
V primerjavi s placebom ni bila opažena pove ana uporaba pri bolnicah, zdravljenih z zdravilom OPTRUMA.
Raloxifene should not be co-administered with cholestyramine (or other anion exchange resins), which significantly reduces the absorption and enterohepatic cycling of raloxifene.
Raloksifena ne smemo dajati so asno s holestiraminom (ali drugimi anionskimi izmenjevalnimi smolami), saj ta pomembno zmanjša absorpcijo in enterohepati no cirkulacijo raloksifena.
Peak concentrations of raloxifene are reduced with co-administration with ampicillin.
So asno jemanje ampicilina zmanjša najvišje koncentracije raloksifena.
However, since the overall extent of absorption and the elimination rate of raloxifene are not affected, raloxifene can be concurrently administered with ampicillin.
Ker pa to ne vpliva na celotni obseg absorpcije in ne na hitrost izlo anja raloksifena iz telesa, lahko raloksifen uporabljamo hkrati z ampicilinom.
Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (SHBG), thyroxine binding globulin (TBG), and corticosteroid binding globulin (CBG), with corresponding increases in total hormone concentrations.
Raloksifen zmerno pove a koncentracije globulinov, na katere se vežejo hormoni, vklju no z globulini, na katere se vežejo steroidni spolni hormoni, globulini, na katere se veže tiroksin, in globulini za vezavo kortikosteroidov, kar povzro i ustrezno pove anje skupne koncentracije hormonov.
4.6 Pregnancy and lactation
4 4. 6 Nose nost in dojenje
OPTRUMA is only for use in postmenopausal women.
Zdravilo OPTRUMA je namenjeno le za zdravljenje žensk po menopavzi.
OPTRUMA must not be taken by women of child bearing potential.
Zdravila OPTRUMA ne smejo jemati ženske v rodni dobi.
If this medicinal product is used mistakenly during pregnancy or the patient becomes pregnant while taking it, the patient should be informed of the potential hazard to the foetus (see section 5.3).
Raloksifen lahko povzro i poškodbe ploda, e ga damo nose i ženski. e ženska to zdravilo pomotoma vzame med nose nostjo ali e bolnica zanosi med jemanjem tega zdravila, jo je treba obvestiti o možni nevarnosti za plod (glejte poglavje 5. 3).
Its clinical use, therefore, cannot be recommended in breast-feeding women.
Ni znano, ali se raloksifen izlo a v materino mleko, zato njegove klini ne uporabe pri doje ih materah ne priporo amo.
OPTRUMA may affect the development of the baby.
Zdravilo OPTRUMA lahko vpliva na dojen kov razvoj.
In osteoporosis treatment and prevention studies involving over 13,000 postmenopausal women all adverse reactionswere recorded.
V raziskavah zdravljenja in prepre evanja osteoporoze, v katerih je sodelovalo ve kot 13. 000 postemnopavzalnih žensk, so beležili vse neželene u inke.
The majority of adverse reactions have not usually required cessation of therapy.
Ve ina neželenih u inkov obi ajno ni zahtevala prekinitve terapije.
In the prevention population discontinuations of therapy due to any adverse reaction occurred in 10.7% of 581 OPTRUMA treated patients and 11.1% of 584 placebo-treated patients.
V populaciji, pri kateri so raloksifen uporabljali za preventivo, so zdravljenje zaradi katerekoli od neželenih u inkov prekinili pri 10, 7% od 581 bolnic, zdravljenih z zdravilom OPTRUMA, in pri 11, 1% od 584 bolnic, ki so prejemale placebo.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8% of 2,557 OPTRUMA treated patients and 11.1% of 2,576 placebo treated patients.
V populaciji, pri kateri so raloksifen uporabljali za zdravljenje, so zdravljenje zaradi kateregakoli od klini nih neželenih dogodkov prekinili pri 12, 8% od 2. 557 bolnic, zdravljenih z zdravilom OPTRUMA, in pri 11, 1% od 2. 576 bolnic, ki so prejemale placebo.
The adverse reactions associated with the use of raloxifene in osteoporosis clinical trials are summarised in the table below.
Neželeni u inki, povezani z uporabo raloksifena v klini nih preskušanjih osteoporoze, so povzeti v tabeli spodaj.
The following convention has been used for the classification of the adverse reactions: very common (1/ 10), common (1/ 100 to < 1/ 10), uncommon (1/ 1,000 to < 1/ 100), rare (1/ 10,000 to < 1/ 1,000) very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Za klasifikacijo neželenih u inkov smo uporabili naslednji dogovor: zelo pogosto (1/ 10), pogosto (1/ 100 do < 1/ 10), ob asno (1/ 1. 000 do < 1/ 100), redko (1/ 10. 000 do < 1/ 1. 000), zelo redko (< 1/ 10. 000), neznano (ocena ni možna iz danih podatkov).
Peripheral oedema
Žilne bolezni Zelo pogosto: vazodilatacija (navali vro ine) Manj pogosto: venski tromboemboli ni zapleti, vklju no z globoko vensko trombozo, plju nimi embolijami, trombozo mrežni nih ven tromboflebitis povrhnjih ven Bolezni miši no- skeletnega sistema in vezivnega tkiva Pogosto: kr i v nogah Splošne težave in spremembe na mestu aplikacije Zelo pogosto: sindrom gripe Pogosto: periferni edem
Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in OPTRUMA patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3% OPTRUMA and 18.2% placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6% for OPTRUMA and 7.1% placebo).
V primerjavi z bolnicami, ki so prejemale placebo, je bila pogostnost pojavov vazodilatacije (navali vro ine) zmerno pove ana pri bolnicah, zdravljenih z zdravilom OPTRUMA (pri klini nih preskušanjih za preventivo osteoporoze, trajanje menopavze 2 do 8 let – 24, 3% pri zdravilu OPTRUMA in 18, 2% pri placebu; pri klini nih raziskavah za zdravljenje osteoporoze, povpre na starost 66 let – 10, 6% pri zdravilu OPTRUMA in 7, 1% pri placebu).
This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.
Ta neželeni u inek je bil najpogostejši v prvih 6 mesecih zdravljenja in se je kasneje le redko pojavil prvi.
In a study of 10,101 postmenopausal women with documented coronary heart disease or at increased risk for coronary events (RUTH), the occurrence of vasodilatation (hot flushes) was 7.8% in the raloxifene-treated patients and 4.7% in the placebo-treated patients.
V študiji 10101 postmenopavzalnih žensk z dokazano koronarno sr no boleznijo ali s pove anim tveganjem za koronarne dogodke (RUTH), je bila pojavnost vazodilatacije (navalov vro ine) pri bolnicah zdravljenih z raloksifenom 7, 8% in 4, 7% pri bolnicah, ki so jemale placebo.
Across all placebo-controlled clinical trials of raloxifene in osteoporosis, venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis occurred at a frequency of approximately 0.8% or 3.22 cases per 1,000 patient years.
5 V vseh klini nih preskušanjih raloksifena pri osteoporozi, nadzorovanih s placebom, so se venski tromboemboli ni zapleti, vklju no s trombozo globokih ven, plju nimi embolijami in trombozo retinalnih ven, pojavljali v približno 0, 8% ali 3, 22 primerih na 1. 000 bolniških let.
A relative risk of 1.60 (CI 0.95, 2.71) was observed in OPTRUMA treated patients compared to placebo.
Pri bolnicah, zdravljenih z zdravilom OPTRUMA, je bilo v primerjavi s tistimi, ki so prejemale placebo, ugotovljeno relativno tveganje 1, 60 (CI 0, 95, 2, 71).
The risk of a thromboembolic event was greatest in the first four months of therapy.
Tveganje za pojav tromboemboli nih zapletov je bilo najve je v prvih štirih mesecih terapije.
In the RUTH study, venous thromboembolic events occurred at a frequency of approximately 2.0% or 3.88 cases per 1000 patient-years in the raloxifene group and 1.4% or 2.70 cases per 1000 patient-years in the placebo group.
V študiji RUTH so se venski tromboemboli ni zapleti pojavljali v približno 2, 0% ali 3, 88 primerih na 1. 000 bolnških let v skupini raloksifena in 1, 4% ali 2, 70 primerih na 1. 000 bolnških let v skupini placeba.
The hazard ratio for all VTE events in the RUTH study was
Razmerje tveganja za vse venske tromboemboli ne zaplete v študiji RUTH je bilo HR = 1, 44, (1, 66 – 1, 95).
Another adverse reaction observed was leg cramps (5.5% for OPTRUMA, 1.9% for placebo in the prevention population and 9.2% for OPTRUMA, 6.0% for placebo in the treatment population).
Naslednji opaženi neželeni u inek so bili kr i v nogah (5, 5% pri zdravilu OPTRUMA in 1, 9% pri placebu v skupini, v kateri so raloksifen uporabljali za preventivo, ter 9, 2% pri zdravilu OPTRUMA in 6, 0% pri placebu v skupini, v kateri so raloksifen uporabljali za zdravljenje).
In the RUTH study, leg cramps were observed in 12.1% of raloxifene-treated patients and 8.3% of placebo-treated patients.
V študiji RUTH so opažali kr e v nogah pri 12, 1% bolnic zdravljenih z raloksifenom in 8, 3% bolnic, ki so jemale placebo.
Flu syndrome was reported by 16.2% of OPTRUMA treated patients and 14.0% of placebo treated patients.
O sindromu gripe so poro ali pri 16, 2% bolnic, zdravljenih z zdravilom OPTRUMA, in pri 14, 0% bolnic, ki so jemale placebo.
One further change was seen which was not statistically significant (p > 0.05), but which did show a significant dose trend.
Opažena je bila še ena sprememba, katere pojavnost ni bila statisti no zna ilna (p > 0, 05), bila pa je v precejšnji meri odvisna od odmerka zdravila.
This was peripheral oedema, which occurred in the prevention population at an incidence of 3.1% for OPTRUMA and 1.9% for placebo; and in the treatment population occurred at an incidence of 7.1% for OPTRUMA and 6.1% for placebo.
To je bil periferni edem, ki se je v skupini, pri kateri so raloksifen uporabljali za preventivo, pojavljal z incidenco 3, 1% za zdravilo OPTRUMA in 1, 9% za placebo ter v skupini, pri kateri so raloksifen uporabljali za zdravljenje, z incidenco 7, 1% za zdravilo OPTRUMA in 6, 1% za placebo.
In the RUTH study, peripheral oedema occurred in 14.1% of the raloxifene-treated patients and 11.7% of the placebo-treated patients, which was statistically significant.
V študiji RUTH se je periferni edem pojavljal pri 14, 1% bolnic zdravljenih z raloksifenom in 11, 7% bolnic, ki so jemale placebo, kar je bilo statisti no zna ilno.
Slightly decreased (6-10%) platelet counts have been reported during raloxifene treatment in placebo- controlled clinical trials of raloxifene in osteoporosis.
Med zdravljenjem z raloksifenom v s placebom nadzorovanih klini nih študijah raloksifena pri osteoporozi so opažali tudi rahlo znižanje (6- 10%) števila trombocitov.
Rare cases of moderate increases in AST and/ or ALT have been reported where a causal relationship to raloxifene can not be excluded.
Poro ali so tudi o redkih primerih zmernega zvišanja AST in/ ali ALT, v katerih ni bilo mogo e izklju iti vzro ne povezave z raloksifenom.
In a study (RUTH) of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an additional adverse reaction of cholelithiasis occurred in 3.3% of patients treated with raloxifene and 2.6% of patients treated with placebo.
V študiji (RUTH) postmenopavzalnih žensk z dokazano koronarno sr no boleznijo ali s pove anim tveganjem za koronarne dogodke se je pojavil dodatni neželeni u inek, holelitiaza pri 3, 3% bolnic zdravljenih z raloksifenom in 2, 6% bolnic, ki so jemale placebo.
Cholecystectomy rates for raloxifene (2.3%) were not statistically significantly different from placebo (2.0%).
Stopnje holecistomije za raloksifen (2, 3%) niso bile statisti no zna ilno druga ne od placeba (2, 0%).
OPTRUMA (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials.
Zdravilo OPTRUMA (n = 317) so v nekaterih klini nih preskušanjih primerjali s kontinuirano kombinirano (n = 110) hormonsko nadomestno terapijo (HRT – hormone replacement therapy) ali s cikli no HRT (n = 205).
The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.
Incidenca simptomov, povezanih z dojkami in krvavitvijo iz maternice, pri bolnicah, zdravljenih z raloksifenom, je bila zna ilno manjša kot pri ženskah, ki so bile zdravljene s katero od obeh oblik HRT.
6 4.9 Overdose
6 Med postmarketinškimi izkušnjami so poro ali o dogodkih, ki so prikazani v tabeli spodaj.
In some clinical trials, daily doses were given up to 600 mg for 8 weeks and 120 mg, for 3 years.
V nekaterih klini nih študijah so dajali dnevne odmerke do 600 mg v asu 8 tednov in 120 mg v asu 3 let.
No cases of raloxifene overdose were reported during clinical trials.
Med temi klini nimi študijami niso poro ali o prevelikem odmerjanju raloksifena.
In adults, symptoms of leg cramps and dizziness have been reported in patients who took more than 120 mg as a single ingestion.
Pri odraslih bolnikih, ki so vzeli ve kot 120 mg raloksifena naenkrat, so poro ali o simptomih kr ev in omotice.
In accidental overdose in children younger than 2 years of age, the maximum reported dose has been 180 mg.
V naklju nem prevelikem odmerjanju pri otrocih, mlajših od 2 let, so poro ali o maksimalnem odmerku 180 mg.
In children, symptoms of accidental overdoseincluded ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase.
Simptomi naklju nega prevelikega odmerjanja pri otrocih so vklju evali ataksijo, omotico, bruhanje, izpuš aj, drisko, tresenje in rde ico ter povišanje alkalne fosfataze.
The highest overdose has been approximately 1.5 grams.
Najve ji preveliki odmerek je bil približno 1, 5 grama.
No fatalities associated with overdose have been reported.
O smrtnih primerih, povezanih s prevelikim odmerjanjem, niso poro ali.
There is no specific antidote for raloxifene hydrochloride.
Specifi nega antidota za raloksifenijev klorid ne poznamo.
ATC code:
Farmakoterapevtska skupina: selektivni modulatorji estrogenskega receptorja, oznaka ATC:
Raloxifene 'biological actions, like those of oestrogen, are mediated through high affinity binding to s oestrogen receptors and regulation of gene expression.
Podobno kot velja za u inke estrogena, raloksifen biološko deluje preko vezave z veliko afiniteto na estrogenske receptorje ter regulacije genske ekspresije.
This binding results in differential expression of multiple oestrogen-regulated genes in different tissues.
Vezava na estrogenske receptorje povzro i razli no ekspresijo ve estrogensko reguliranih genov v razli nih tkivih.
Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/ or gene-specific.
Novejši podatki kažejo, da lahko estrogenski receptor regulira gensko ekspresijo po vsaj dveh razli nih poteh, ki sta specifi ni za ligand, tkivo in/ ali gen.
a) Skeletal Effects
7 a) Vplivi na okostje